These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28642029)

  • 41. Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib.
    de Bruin G; Mock ED; Hoogendoorn S; van den Nieuwendijk AM; Mazurek J; van der Marel GA; Florea BI; Overkleeft HS
    Chem Commun (Camb); 2016 Mar; 52(21):4064-7. PubMed ID: 26894389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthetic Photoswitchable Neurotransmitters Based on Bridged Azobenzenes.
    Cabré G; Garrido-Charles A; González-Lafont À; Moormann W; Langbehn D; Egea D; Lluch JM; Herges R; Alibés R; Busqué F; Gorostiza P; Hernando J
    Org Lett; 2019 May; 21(10):3780-3784. PubMed ID: 31070376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent Progress in Regulating the Activity of Enzymes with Photoswitchable Inhibitors.
    Chen Y
    Molecules; 2024 Sep; 29(19):. PubMed ID: 39407453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.
    Larsson P; De Rosa MC; Righino B; Olsson M; Florea BI; Forssell-Aronsson E; Kovács A; Karlsson P; Helou K; Parris TZ
    Sci Rep; 2024 Aug; 14(1):18772. PubMed ID: 39138277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the ubiquitin+proteasome system in solid tumors.
    Driscoll JJ; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog.
    Sheldon JE; Dcona MM; Lyons CE; Hackett JC; Hartman MC
    Org Biomol Chem; 2016 Jan; 14(1):40-9. PubMed ID: 26503632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metal complexes as inhibitors of the 26S proteasome in tumor cells.
    Verani CN
    J Inorg Biochem; 2012 Jan; 106(1):59-67. PubMed ID: 22112841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Total synthesis and absolute stereochemistry of the proteasome inhibitors cystargolides A and B.
    Tello-Aburto R; Hallada LP; Niroula D; Rogelj S
    Org Biomol Chem; 2015 Oct; 13(40):10127-30. PubMed ID: 26400369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urea-containing peptide boronic acids as potent proteasome inhibitors.
    Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
    Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
    Perez C; Li J; Parlati F; Rouffet M; Ma Y; Mackinnon AL; Chou TF; Deshaies RJ; Cohen SM
    J Med Chem; 2017 Feb; 60(4):1343-1361. PubMed ID: 28191850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proteasome inhibitors: introduction.
    Heuck CJ; Shaughnessy JD
    Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone.
    Nakamura K; Yang JH; Sato E; Miura N; Wu YX
    Biol Pharm Bull; 2015; 38(6):935-40. PubMed ID: 25810454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and pharmacology of proteasome inhibitors.
    Rentsch A; Landsberg D; Brodmann T; Bülow L; Girbig AK; Kalesse M
    Angew Chem Int Ed Engl; 2013 May; 52(21):5450-88. PubMed ID: 23526565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacophore modeling technique applied for the discovery of proteasome inhibitors.
    Pautasso C; Troia R; Genuardi M; Palumbo A
    Expert Opin Drug Discov; 2014 Aug; 9(8):931-43. PubMed ID: 24877566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
    Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.
    Totaro KA; Barthelme D; Simpson PT; Sauer RT; Sello JK
    Bioorg Med Chem; 2015 Sep; 23(18):6218-22. PubMed ID: 26296913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system.
    Selvaraju K; Mofers A; Pellegrini P; Salomonsson J; Ahlner A; Morad V; Hillert EK; Espinosa B; Arnér ESJ; Jensen L; Malmström J; Turkina MV; D'Arcy P; Walters MA; Sunnerhagen M; Linder S
    Sci Rep; 2019 Jul; 9(1):9841. PubMed ID: 31285509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 1H NMR assay for measuring the photostationary States of photoswitchable ligands.
    Banghart MR; Trauner D
    Methods Mol Biol; 2013; 995():107-20. PubMed ID: 23494375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Red-Shifting Azobenzene Photoswitches for in Vivo Use.
    Dong M; Babalhavaeji A; Samanta S; Beharry AA; Woolley GA
    Acc Chem Res; 2015 Oct; 48(10):2662-70. PubMed ID: 26415024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.